45
Participants
Start Date
January 3, 2014
Primary Completion Date
May 20, 2015
Study Completion Date
January 6, 2017
Blinatumomab
Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.
Research Site, New York
Research Site, Berlin
Research Site, Bergamo
Research Site, Durham
Research Site, Venezia
Research Site, Atlanta
Research Site, Toulouse
Research Site, Verona
Research Site, Bologna
Research Site, Nantes
Research Site, Essen
Research Site, Rochester
Research Site, Frankfurt am Main
Research Site, St Louis
Research Site, Paris
Research Site, Houston
Research Site, Duarte
Research Site, Würzburg
Research Site, La Jolla
Research Site, Roma
Research Site, London
Research Site, Sutton
Lead Sponsor
Amgen
INDUSTRY